Insulet (PODD)
(Delayed Data from NSDQ)
$236.59 USD
+7.46 (3.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $237.00 +0.41 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.59 USD
+7.46 (3.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $237.00 +0.41 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Zacks News
National Vision's (EYE) Market Expansion Aids, Inflation Ails
by Zacks Equity Research
National Vision (EYE) is expanding sales by the continued rollout of its remote medicine technology.
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
by Zacks Equity Research
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.
Medtronic's (MDT) Symplicity Spyral RDN System Gets FDA Boost
by Zacks Equity Research
Medtronic (MDT) receives the FDA approval for Symplicity blood pressure procedure for the treatment of hypertension.
Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics
by Zacks Equity Research
Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
by Zacks Equity Research
The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.
Neogen's (NEOG) Innovation Aids, Currency Headwind Stays
by Zacks Equity Research
Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
by Zacks Equity Research
Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.
Paragon 28 (FNA) New Staple System Expands Ankle Device Line
by Zacks Equity Research
Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.
Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes
by Zacks Equity Research
Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.
Illumina (ILMN) Launches Initiative on Pathogen Sequencing
by Zacks Equity Research
Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.
Encompass Health (EHC) Opens Hospital to Boost Presence in Texas
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.
Prestige Consumer's (PBH) Brand Building, Innovation Aid Growth
by Zacks Equity Research
Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.
QIAGEN (QGEN) Launches QIAcuity Kits and Software Update
by Zacks Equity Research
QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.
IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis
by Zacks Equity Research
IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.
3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)
by Zacks Equity Research
Insulet (PODD) could produce exceptional returns because of its solid growth attributes.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.
Surging Earnings Estimates Signal Upside for Insulet (PODD) Stock
by Zacks Equity Research
Insulet (PODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Chemed's (CHE) VITAS Performance Aids, Macro Issues Linger
by Zacks Equity Research
Chemed (CHE) believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment's market share.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Here's How Much a $1000 Investment in Insulet Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research
by Zacks Equity Research
QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.